TOVX (TOVX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

TOVX (TOVX) Healthcare & Pipeline Overview

Theriva Biologics Inc. (TOVX) is a clinical-stage biotechnology firm developing novel therapies for unmet medical needs, particularly in gastrointestinal diseases and microbiome damage. Its lead candidates, SYN-004 and SYN-020, are progressing through clinical trials, positioning the company within a competitive biotechnology landscape focused on innovative solutions.

What Is the Investment Thesis for TOVX?

Theriva Biologics (TOVX) presents a high-risk, high-reward investment opportunity. The company's value hinges on the successful clinical development and commercialization of its lead product candidates, SYN-004 and SYN-020. Positive clinical trial results for SYN-004 in preventing microbiome damage and CDI, and for SYN-020 in treating GI and systemic diseases, would serve as major catalysts. The potential market for these therapies is substantial, given the increasing prevalence of antibiotic resistance and GI disorders. However, the company's negative ROE of -201.8% and small market capitalization of $10.6M highlight the financial risks. Investors should carefully consider the inherent uncertainties of biotechnology investments, including regulatory hurdles, clinical trial failures, and the need for additional funding.

Based on FMP financials and quantitative analysis

TOVX Key Highlights

Market capitalization of $10.6M, indicating a micro-cap company with high growth potential but also higher risk.

• Beta of 0.47, suggesting the stock is less volatile than the overall market.
• No dividend yield, typical for clinical-stage biotechnology companies that reinvest earnings into research and development.
• Focus on addressing unmet needs in gastrointestinal diseases and microbiome damage, areas with significant market potential.
• Clinical-stage pipeline with multiple product candidates, including SYN-004 and SYN-020, offering multiple potential value inflection points.

Who Are TOVX's Competitors?

TOVX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TOVX's Key Strengths?

Focus on high unmet medical needs.

• Proprietary drug candidates with patent protection.
• Collaborations with leading research institutions.
• Experienced management team.

What Are TOVX's Weaknesses?

Limited financial resources.

• Dependence on clinical trial success.
• Competition from larger pharmaceutical companies.
• Negative ROE of -201.8%

What Could Drive TOVX Stock Higher?

Data readout from Phase 1b/2a clinical trial of SYN-004 in Q3 2026.

• Initiation of Phase 2 clinical trial for SYN-020 in Q4 2026.
• Continued enrollment in ongoing clinical trials for VCN-01.
• Potential for new strategic collaborations to expand pipeline.

What Are the Key Risks for TOVX?

Financial-distress signal — its Altman Z-Score of -15.38 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-93.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for SYN-004, SYN-020, or VCN-01.
• Regulatory delays or rejection of product candidates.
• Competition from other biotechnology and pharmaceutical companies.
• Need for additional funding to support clinical development.
• Negative ROE of -201.8% indicating financial instability.

What Are the Growth Opportunities for TOVX?

• Advancement of SYN-004: SYN-004, designed to prevent microbiome damage and CDI, represents a significant growth opportunity. The increasing prevalence of antibiotic resistance and CDI creates a substantial market for effective preventative therapies. Successful completion of the Phase 1b/2a clinical trial with Washington University School of Medicine in St. Louis and subsequent commercialization could drive significant revenue growth.
• Development of SYN-020: SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase, targets both local GI and systemic diseases. Its potential to treat a range of inflammatory and immune-related disorders offers a broad market opportunity. Positive clinical trial results and subsequent regulatory approval could position SYN-020 as a valuable therapeutic option. The market for treatments addressing inflammatory bowel disease and other GI disorders is substantial and growing.
• Expansion of VCN-01: VCN-01, targeting various cancers including pancreatic cancer and head and neck squamous cell carcinoma, represents a significant growth driver. The oncology market is characterized by high unmet needs and premium pricing. Successful clinical development and commercialization of VCN-01 could generate substantial revenue.
• Strategic Collaborations: Theriva's collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center provide access to valuable expertise and resources. These collaborations can accelerate the development of its product candidates and expand its technological capabilities. Strategic partnerships can also provide access to funding and commercialization opportunities, enhancing Theriva's growth prospects. Continued cultivation of strategic alliances will be crucial for long-term success.
• Pipeline Expansion: Theriva's pipeline includes SYN-006, SYN-007, SYN-005, and VCN-11, targeting aGVHD, antibiotic-associated diarrhea, pertussis, and cancer, respectively. Advancing these programs through clinical development will diversify the company's product portfolio and reduce its reliance on SYN-004 and SYN-020. Successful development of these additional therapies could significantly increase Theriva's market capitalization and revenue potential. A diversified pipeline is essential for mitigating the risks inherent in biotechnology development.

What Are TOVX's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Specialized expertise in microbiome-related therapies.
• Clinical trial data demonstrating safety and efficacy.
• Collaborations with leading research institutions.

What Does TOVX Do?

Theriva Biologics Inc., formerly known as Synthetic Biologics, Inc., was founded with the mission of developing innovative therapeutics to address diseases with significant unmet medical needs. The company changed its name in October 2022 to reflect its evolving focus. Theriva's core focus lies in the development of treatments for gastrointestinal (GI) diseases, microbiome damage, and cancer. Their lead product candidates include SYN-004, designed to degrade intravenous beta-lactam antibiotics in the GI tract, aiming to prevent microbiome damage, Clostridium difficile infection (CDI), and antimicrobial resistance (AMR). SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase, is being developed to treat both local GI and systemic diseases. Additionally, Theriva is developing VCN-01 for various cancers, including pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. The company's pipeline also includes SYN-006, SYN-007, SYN-005, and VCN-11, targeting aGVHD, antibiotic-associated diarrhea, pertussis, and cancer, respectively. Theriva Biologics collaborates with institutions like Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center, and has a clinical trial agreement with Washington University School of Medicine in St. Louis for SYN-004. Headquartered in Rockville, Maryland, Theriva Biologics operates as a clinical-stage company, navigating the complex landscape of drug development and regulatory approvals.

What Products and Services Does TOVX Offer?

• Develop therapeutics for diseases with high unmet needs.
• Focus on gastrointestinal diseases and microbiome damage.
• Develop SYN-004 to prevent microbiome damage and CDI.
• Develop SYN-020 to treat local GI and systemic diseases.
• Develop VCN-01 for the treatment of various cancers.
• Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
• Collaborate with research institutions and other companies to advance their programs.

How Does TOVX Make Money?

• Develop and patent novel therapeutic candidates.
• Out-license or partner with larger pharmaceutical companies for commercialization.
• Generate revenue through milestone payments and royalties from partnered products.
• Potentially commercialize products directly if resources allow.

What Industry Does TOVX Operate In?

Theriva Biologics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for microbiome-related therapies is expanding, driven by increasing awareness of the gut microbiome's role in overall health. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms focusing on similar therapeutic areas. Theriva's success depends on its ability to navigate the complex clinical trial process, secure regulatory approvals, and effectively commercialize its products. The biotechnology industry is subject to rapid technological advancements and shifting market dynamics, requiring companies to remain agile and adaptable.

Who Are TOVX's Key Customers?

• Hospitals and healthcare providers treating patients with CDI.
• Patients at risk of microbiome damage due to antibiotic use.
• Patients suffering from inflammatory bowel disease and other GI disorders.
• Patients with various cancers, including pancreatic cancer and head and neck squamous cell carcinoma.

Return on equity for TOVX stands at -93.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.3%, showing how much profit it generates from its asset base. A current ratio of 1.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -110.1%, the inverse of the P/E and a quick read on earnings relative to price.

TOVX (TOVX) Valuation Context

Valued at $10.6M, TOVX is classified as a micro-cap stock. Relative to its peer group, TOVX's quantitative score of 18/100 is below the peer average of 77/100.

Company Profile

TOVX operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO Steven A. Shallcross. TOVX has traded publicly since 2006.

TOVX's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.38 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project TOVX revenue of about $300K for fiscal 2026, with EPS near $-0.23.

TOVX Financials

TOVX Latest News

TOVX Analyst Consensus

TOVX MoonshotScore

Latest TOVX Analysis

TOVX Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources